Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM6B6E)

Drug Name

SelK2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]
Chronic obstructive pulmonary disease	CA22	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting P-selectin glycoprotein ligand 1 (SELPLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AbGn-168	DMT6H3J	Allergy	4A80-4A85	Phase 2	[3]
Neihulizumab	DMUPZFO	Psoriatic arthritis	FA21	Phase 2	[4]
RO-4905417	DMV319J	Acute coronary syndrome	BA41	Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P-selectin glycoprotein ligand 1 (SELPLG)	TTS5K8U	SELPL_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04540042) A Two Part, Randomised, Double-blind, Placebo-controlled, Phase 2 Parallel Group Study to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 in Subjects With Chronic Obstructive Pulmonary Disease (Part 2). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Tetherex Pharmaceuticals
3	Clinical pipeline report, company report or official report of Avarx.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	WO patent application no. 2013,0144,05, Methods.